Commercial Alamar, Hemab, Kailera, and Seaport advance IPOs PharmaphorumThe last few days have seen a flurry of biotech IPO news, with Alamar, Hemab, Kailera, and Seaport all pushing for Nasdaq listings.CommercialRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaphorum The last few days have seen a flurry of biotech IPO news, with Alamar, Hemab, Kailera, and Seaport all pushing for Nasdaq listings. CommercialRead full story Post navigation Previous: Spyre drug for inflammatory bowel disease shows promise in early studyNext: MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority Related Stories Commercial Novo’s CEO champions “record-breaking start” for Wegovy pill in US market pharminent May 8, 2026 Commercial Novo hikes guidance on Wegovy pill’s fast sales start pharminent May 6, 2026 Commercial Novo’s Wegovy pill reaches 1M patients, shattering expectations with $355M in sales pharminent May 6, 2026
